2015
A21 A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer
Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A21 A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer. Annals Of Oncology 2015, 26: vi9. DOI: 10.1093/annonc/mdv336.21.Peer-Reviewed Original Research
2009
Different Biological Processes Are Associated with Prognosis and Chemotherapy Sensitivity in the Different Molecular Subtypes of Breast Cancer.
Iwamoto T, Iwamoto T, Bianchini G, Coutant C, Shiang C, Matsuoka J, Symmans W, Hortobagyi G, Simon R, Pusztai L. Different Biological Processes Are Associated with Prognosis and Chemotherapy Sensitivity in the Different Molecular Subtypes of Breast Cancer. Cancer Research 2009, 69: 6124-6124. DOI: 10.1158/0008-5472.sabcs-09-6124.Peer-Reviewed Original ResearchER- cancersDifferent molecular subtypesChemotherapy sensitivityChemotherapy responseBreast cancerMolecular subtypesMeta-AnalysisPrognostic pathwaysCohort of patientsPlasma cell functionT cell differentiationNeoadjuvant therapySeparate cohortImmune functionPrognosisGlycolipid metabolismPredictive gene setsBlood vessel formationDifferent subtypesCancerCancer ResOxidative stressCell functionSubtypesVessel formation